Zydus Lifesciences has launched Semaglutide Injection under the brand names � SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications. Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, Zydus offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost. Zydus` Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of the treatment will be approximately Rs. 2,200.Powered by Capital Market - Live News

Zydus Lifesciences has launched Aerolife Mini�, a next-generation pMDI enhancer marking a significant step in the company`s strategy to drive drug device led innovation that in respiratory care. Aerolife Mini� is India`s first portable and foldable spacer, making it highly convenient to use. Zydus has launched this device under an exclusive licensing arrangement with AeroDel Technology Innovations.Aerolife Mini� introduces a compact, foldable, and ready to use design that fundamentally redefines how spacers are used. The drug device is expected to achieve better drug deposition, improve compliance enhance patient confidence and provide greater convenience. Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Cevimeline Hydrochloride Capsules 30 mg, (USRLD: Evoxac� Capsules, 30 mg). Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sj�gren`s syndrome. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion. Cevimeline hydrochloride 30 mg capsules will be produced at the Group`s manufacturing facility at SEZ-II, Ahmedabad. Cevimeline Hydrochloride Capsules 30mg had annual sales of USD 26.9 mn. (IQVIA MAT Jan-26).Powered by Capital Market - Live News

Zydus Lifesciences announced its new offering companion diagnostics portfolio. The company will be launching Diasens and GlucoLive, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time. Zydus has partnered with Digicare Health Solutions (TatvaCare), a healthcare technology company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlip to provide AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault - all in a single mobile application. Powered by Capital Market - Live News

Zydus Lifesciences has received final approvals from the United States Food and Drug Administration (USFDA) for Ivermectin Tablets USP, 3 mg (USRLD: Stromectol� Tablets, 3 mg) and Dapsone Tablets USP, 25 mg and 100 mg (USRLD: Dapsone Tablets USP, 25 mg and 100 mg). Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans, specifically intestinal strongyloidiasis and onchocerciasis. Ivermectin tablets will be manufactured at the group`s formulation manufacturing facility at SEZ, Ahmedabad and distributed by Viona Pharmaceuticals Inc. Ivermectin Tablets USP, 3 mg had annual sales of USD 14.8 mn Dapsone Tablets USP, 25 mg and 100 mg are indicated for the treatment of leprosy (all forms, including multibacillary and paucibacillary) and dermatitis herpetiformis. It acts as an anti-infective and antibacterial agent and is used to control skin lesions in dermatitis herpetiformis and for leprosy. Dapsone tablets will be manufactured at the group`s formulation manufacturing facility at SEZ-II, Ahmedabad and distributed by Viona Pharmaceuticals Inc. Dapsone Tablets USP, 25 mg and 100 mg had annual sales of USD 8.4 mn in the United States (IQVIA MAT December 2025).Powered by Capital Market - Live News